MRI scans could replace invasive heart tests for lung disease patients
NCT ID NCT05624242
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether cardiac MRI can accurately measure right heart function in 112 people with pulmonary arterial hypertension. Researchers compared MRI results with data from invasive heart catheterization. The goal was to see if MRI could be used to monitor disease and predict outcomes like need for transplant or death.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors use MRI instead of invasive catheterization to monitor heart function in pulmonary hypertension patients.
- What could go wrong
- This is an observational study, not a treatment trial. It may not change current practice if MRI does not prove reliable enough to replace invasive testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
112 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population concerns patients with pulmonary arterial hypertension (group 1 or 4) followed up in our centre, at diagnosis and when starting vasodilator treatment.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient with pulmonary arterial hypertension (group 1) or chronic thrombo-embolic pulmonary hypertension (group 4) * Patient with cardiac MRI and right heart catheterisation within 1 month or without drug modification between the two Exclusion Criteria: * Patient with features of venous/capillary involvement * Pulmonary arterial hypertension associated with with congenital heart disease * Patient's decline to participate in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic thromboembolic pulmonary hypertension are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Simon Valentin
Nancy, Grand Est, 54000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- A 10-Question survey could give brazilian pulmonary hypertension patients a voice in their care
- Experimental blood pressure drug put to the test in healthy volunteers
- Can a new drug keep pulmonary arterial hypertension in check over the long haul?
- Could light leg workouts revive Oxygen-Starved muscles in PAH?
- Texting therapy: could a simple phone message boost exercise and quality of life in a rare lung disease?